Fight Aging!

Microglia are innate immune cells of the brain, similar in behavior to tissue resident macrophages elsewhere in the body, but with an additional portfolio of duties relating to maintenance of neural networks. Like macrophages, microglia can adopt packages of behavior, and switch between them depending on environment cues; pro-inflammatory M1 focused on defense against pathogens versus anti-inflammatory M2 focused on tissue maintenance, for example. With age, the microglial population becomes more inflammatory, contributing to chronic inflammation of brain tissue and consequent disruption of normal function that contributes to the onset and progression of neurodegenerative conditions. Some of this inflammatory behavior is a consequence of an increased burden of cellular senescence in microglia and other supporting cells of the brain, but not all of it. Regardless, microglial dysfunction is a topic of increasing interest for researchers aiming to produce novel therapies to address the aging of the brain.

An active area of exploration is the contribution of lipid metabolism dysfunction to the inflammatory behavior of microglia in the aging brain. Of particular interest is the point that variants of APOE are well demonstrated to alter the risk of Alzheimer's disease, this protein is deeply involved in lipid metabolism, and evidence suggests it contributes to microglial inflammation. A further point is that excess cholesterol in cells can cause mitochondrial dysfunction, and the aging brain (and particularly in neurodegenerative conditions) exhibits both of these features. Finding specific dysfunctions in lipid metabolism and then attempting to address them with novel therapies seems a promising area of exploration in neurodegenerative research. Today's open access paper discusses evidence for the involvement of lysosomal aging in dysfunctional lipid metabolism in microglia, another possible starting point for a search for novel treatments.

Dysfunction of lipid metabolism and lysosomal capacity: at the core of microglial aging?

The metabolism of lipids is emerging as an essential regulator of microglial homeostatic activity and the ability to adapt their functional state to environmental changes across the lifespan. Microglial lipids serve structural roles in membrane maintenance and remodeling and act as signaling mediators in key regulatory pathways, including energy production and inflammatory mediator release. Beyond their intrinsic lipid needs, microglia phagocytose lipid-rich substrates (i.e., myelin fragments, cell debris, and synaptic elements) and generate intracellular lipid cargo through housekeeping autophagic processes. Intracellular lipid droplets (LD), which store excess lipids, are emerging as essential regulators of microglial metabolic programming and functional capacity. To maintain lipid balance and prevent lipotoxicity, microglia possess a complex feedback-regulated system for lipid uptake, processing, recycling, storage and export of excess lipids. Lysosomes, the cellular degradative and signaling hubs, lie at the center of these key lipid-handling pathways, both organizing lipid turnover and being modulated by the lipid status. This bi-directional interplay underlying microglial metabolic programming is coordinated by a variety of lipid- and nutrient-sensing molecular players, notably involving mechanistic target of rapamycin complex 1 (mTORC1) or triggering receptor expressed on myeloid cells 2 (TREM2).

Aging drives maladaptive microglial functions contributing to inflammation and neurotoxicity in age-associated disorders. Dysfunctional lipid handling and lysosomal processing have been connected to this detrimental polarization, highlighting the relevance of this pathway for therapeutic targeting. While significant advances have been made in the study of microglial lipid metabolism in contexts of aging-related diseases, our understanding of its changes over the course of physiological aging remains lacking, which creates a critical knowledge gap. Several single-cell analyses further indicate that microglial aging occurs in a central nervous system region-dependent manner, raising fundamental questions: (1) is this regional heterogeneity associated with distinct microglial lipid signatures and/or lysosomal capacities; (2) do these putative baseline differences play a role in susceptibility to and extent of aging-related microglial dysfunction; and (3) is microglial lipid shift inherent and/or driven by environmental challenges? On a broader level, how these metabolic and functional aging microglial changes are translated into higher cognitive processes, and what role they play in their aging-associated decline and disease susceptibility, represents a crucial area for investigation.